XML 68 R52.htm IDEA: XBRL DOCUMENT
v3.19.3

License agreements - Novartis (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 119 Months Ended
--- | --- | --- | --- | --- | ---
Apr. 30, 2016 USD ($) | Sep. 30, 2014 USD ($) | Jan. 31, 2010 USD ($) | Dec. 31, 2009 USD ($) | Nov. 30, 2009 USD ($) item | Sep. 30, 2019 USD ($) | Sep. 30, 2018 USD ($) | Sep. 30, 2019 USD ($) | Sep. 30, 2018 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Dec. 31, 2013 USD ($) | Dec. 31, 2012 USD ($) | Dec. 31, 2011 USD ($) | Dec. 31, 2010 USD ($) | Sep. 30, 2019 USD ($)
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  | $ 551,581 | $ 449,683 | $ 1,579,370 | $ 1,353,481 |  |  |  |  |  |  |  |  |  |
JAKAFI |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  | 433,387 | 347,567 | 1,218,504 | 1,006,911 |  |  |  |  |  |  |  |  |  |
Novartis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  |  |  | $ 210,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received under license agreement |  |  |  | $ 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Immediate milestone payment received under license agreement |  |  | $ 60,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  | 0 |  | 0 |  |  |  |  |  |  |  |  |  |  |
Royalties payable |  |  |  |  |  | 38,000 |  | 38,000 |  | $ 18,600 |  |  |  |  |  |  |  |  | $ 38,000
Number of deliverables under license agreement | item |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursable costs recorded as deferred revenue |  |  |  | $ 10,900 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursable costs included in accounts receivable |  |  |  |  |  | 600 |  | 600 |  | 700 |  |  |  |  |  |  |  |  | 600
Research and development expenses reimbursed |  |  |  |  |  | 0 | 1,200 | 1,000 | 2,400 |  |  |  |  |  |  |  |  |  |
Product royalties in accounts receivable |  |  |  |  |  | 58,400 |  | 58,400 |  | 55,400 |  |  |  |  |  |  |  |  | 58,400
Novartis | Pre-specified Events | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  |  |  | $ 1,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis | Development Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 132,000
Novartis | Development Milestones | Phase III |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000 |
Novartis | Development Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  |  |  | 174,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis | Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 215,000
Novartis | Regulatory Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  |  |  | 495,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis | Commercialization Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  | 60,000 |  |  |  |  |  |  |  |  | $ 120,000
Revenues |  |  |  |  |  |  |  |  |  | $ 900,000 |  |  |  |  |  |  |  |  |
Novartis | Commercialization Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis | LY3009104 | Development Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 | $ 7,000 | $ 25,000 |  | $ 15,000 |  |
Novartis | GVHD | Development Milestones | Phase III |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |  |
Novartis | GVHD | Development and Regulatory Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement | $ 75,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis | GVHD | Development and Commercialization Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  |  |  |  |  |  |
Novartis | JAKAFI | U.S. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties payable on net sales |  |  |  |  |  | 21,200 | 17,000 | 54,700 | 44,300 |  |  |  |  |  |  |  |  |  |
Novartis | JAKAFI | Regulatory Milestones | Europe |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  |  | $ 40,000 | 25,000 | 60,000 |  | $ 40,000 |  |  |
Novartis | JAKAFI | Regulatory Milestones | JAPAN |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 25,000 |  |  |  |  |
Novartis | JAKAFI | Regulatory Milestones | U.S. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000 |  |
Novartis | JAKAVI |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  | $ 58,400 | $ 50,900 | $ 160,900 | $ 139,400 |  |  |  |  |  |  |  |  |  |
Novartis | JAKAVI | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  |  |  |  |  | 12.00% |  |  |  |  |  |  |  |  |  |  |
Novartis | JAKAVI | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  |  |  |  |  | 14.00% |  |  |  |  |  |  |  |  |  |  |
Novartis | JAKAVI | Regulatory Milestones | Europe |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  | $ 60,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis | JAKAVI | Regulatory Milestones | JAPAN |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  |  |  | 15,000 |  |  |  |  |  |
Novartis | JAKAVI | Commercialization Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount recognized and received for the achievement of a predefined milestone |  |  |  |  |  |  |  |  |  |  | 40,000 |  | 20,000 |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  | $ 600,000 |  | $ 300,000 |  |  |  |  |  |

X
- Definition Represents reimbursable costs incurred and recorded as deferred revenue on the condensed consolidated balance sheet. + References No definition available. + Details
Name: | incy_DeferredReimbursableCost
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the immediate milestone payment received under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementImmediateMilestonePaymentReceived
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the number of deliverables under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementNumberOfDeliverables
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents reimbursable costs pertaining to license agreements. + References No definition available. + Details
Name: | incy_LicenseAgreementReimbursableCosts
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents reimbursed costs pertaining to research and development expenses. + References No definition available. + Details
Name: | incy_LicenseAgreementResearchAndDevelopmentReimbursedCost
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the upfront and immediate milestone payment received under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the upfront payment received under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementUpfrontPaymentReceived
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized. + References No definition available. + Details
Name: | incy_PercentageOfRoyaltyRatePayments
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of royalties payable. + References No definition available. + Details
Name: | incy_RoyaltiesPayable
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the royalty payment receivable under the license agreement. + References No definition available. + Details
Name: | incy_RoyaltyPaymentReceivable
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_IncreaseDecreaseInRoyaltiesPayable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=incy_JAKAFIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_PreSpecifiedEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_PhasesOfArrangementsAxis=incy_PhaseThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=incy_LY3009104Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=incy_GvhdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndCommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=incy_JakaviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |